Cardiff Oncology, Inc. (CRDF) stock
CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.85−0.04 (-4.46%)
Close on Nov 20, 2026Market cap $66.34MP/E –Yield –
Cardiff Oncology total assets
Total assets on the balance sheet at the end of each period.
Cardiff Oncology's total assets was $37.33M at Jun 30, 2026. For fiscal 2025 it was $61.88M, down 36.3% from the year before. Over ten years it grew -1.4% a year on average. The highest annual figure on record is $149.54M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.88M | -36.3% |
| FY2024 | Dec 31, 2024 | $97.19M | +19.1% |
| FY2023 | Dec 31, 2023 | $81.64M | -29.7% |
| FY2022 | Dec 31, 2022 | $116.19M | -22.3% |
| FY2021 | Dec 31, 2021 | $149.54M | +11.0% |
| FY2020 | Dec 31, 2020 | $134.73M | +929.5% |
| FY2019 | Dec 31, 2019 | $13.09M | -7.7% |
| FY2018 | Dec 31, 2018 | $14.17M | +15.4% |
| FY2017 | Dec 31, 2017 | $12.28M | -72.0% |
| FY2016 | Dec 31, 2016 | $43.95M | -38.5% |
| FY2015 | Dec 31, 2015 | $71.45M | +147.2% |
| FY2014 | Dec 31, 2014 | $28.90M | +6.4% |
| FY2013 | Dec 31, 2013 | $27.16M | +132.8% |
| FY2012 | Dec 31, 2012 | $11.67M | +1022.4% |
| FY2011 | Dec 31, 2011 | $1.04M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $37.33M | -50.7% |
| Q1 FY2026 | Mar 31, 2026 | $49.17M | -42.0% |
| Q4 FY2025 | Dec 31, 2025 | $61.88M | -36.3% |
| Q3 FY2025 | Sep 30, 2025 | $63.78M | +1.4% |
| Q2 FY2025 | Jun 30, 2025 | $75.74M | +14.7% |
| Q1 FY2025 | Mar 31, 2025 | $84.81M | +14.5% |
| Q4 FY2024 | Dec 31, 2024 | $97.19M | +19.1% |
| Q3 FY2024 | Sep 30, 2024 | $62.90M | -28.9% |
| Q2 FY2024 | Jun 30, 2024 | $66.05M | -32.2% |
| Q1 FY2024 | Mar 31, 2024 | $74.04M | -30.5% |
| Q4 FY2023 | Dec 31, 2023 | $81.64M | -29.7% |
| Q3 FY2023 | Sep 30, 2023 | $88.45M | -28.5% |
| Q2 FY2023 | Jun 30, 2023 | $97.46M | -25.8% |
| Q1 FY2023 | Mar 31, 2023 | $106.55M | -23.5% |
| Q4 FY2022 | Dec 31, 2022 | $116.19M | -22.3% |
| Q3 FY2022 | Sep 30, 2022 | $123.63M | -12.5% |
| Q2 FY2022 | Jun 30, 2022 | $131.26M | -8.7% |
| Q1 FY2022 | Mar 31, 2022 | $139.20M | +7.4% |
| Q4 FY2021 | Dec 31, 2021 | $149.54M | +11.0% |
| Q3 FY2021 | Sep 30, 2021 | $141.31M | +258.2% |
| Q2 FY2021 | Jun 30, 2021 | $143.73M | +377.1% |
| Q1 FY2021 | Mar 31, 2021 | $129.57M | +996.6% |
| Q4 FY2020 | Dec 31, 2020 | $134.73M | +929.5% |
| Q3 FY2020 | Sep 30, 2020 | $39.45M | +230.9% |
| Q2 FY2020 | Jun 30, 2020 | $30.13M | +117.3% |
| Q1 FY2020 | Mar 31, 2020 | $11.82M | -18.7% |
| Q4 FY2019 | Dec 31, 2019 | $13.09M | -7.7% |
| Q3 FY2019 | Sep 30, 2019 | $11.92M | -33.5% |
| Q2 FY2019 | Jun 30, 2019 | $13.87M | -36.3% |
| Q1 FY2019 | Mar 31, 2019 | $14.53M | +39.6% |
| Q4 FY2018 | Dec 31, 2018 | $14.17M | +15.4% |
| Q3 FY2018 | Sep 30, 2018 | $17.92M | +46.7% |
| Q2 FY2018 | Jun 30, 2018 | $21.77M | +73.3% |
| Q1 FY2018 | Mar 31, 2018 | $10.41M | -69.3% |
| Q4 FY2017 | Dec 31, 2017 | $12.28M | -72.0% |
| Q3 FY2017 | Sep 30, 2017 | $12.22M | -76.9% |
| Q2 FY2017 | Jun 30, 2017 | $12.56M | – |
| Q1 FY2017 | Mar 31, 2017 | $33.93M | – |
| Q4 FY2016 | Dec 31, 2016 | $43.95M | – |
| Q3 FY2016 | Sep 30, 2016 | $53.00M | – |
See a number that looks wrong?